Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT05308446	TitleTesting the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation	Fase Fase 2	Date Added 2022-04-04	Ubicación Arizona, United States California, United States Colorado, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Louisiana, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States New Hampshire, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Washington, United States West Virginia, United States Wisconsin, United States Puerto Rico	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas cetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, Opdivo	Etiquetas MSS/ MMRp
NCT ID NCT06102902	TitleTesting the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Refractory BRAF V600E mCRC	Fase Fase 1	Date Added 2023-10-26	Ubicación California, United States Kansas, United States Ohio, United States Oklahoma, United States Texas, United States Virginia, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas BET Bromodomain Inhibitor ZEN-3694, encorafenib	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03368963	TitleTAS102 in Combination With NAL-IRI in Advanced GI Cancers	Fase Phase 1, Phase 2	Date Added 2017-12-11	Ubicación Georgia, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT02465060	TitleTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	Fase Fase 2	Date Added 2015-06-08	Ubicación Alabama, United States Alaska, United States Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Delaware, United States District of Columbia, United States Florida, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maine, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Virginia, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States Guam Puerto Rico	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas Adavosertib, afatinib, Afatinib Dimaleate, Binimetinib, Capivasertib, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Larotrectinib Sulfate, Nivolumab, Osimertinib, palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab emtansine, Ulixertinib, Vismodegib	Etiquetas MSS/ MMRp
NCT ID NCT02693535	TitleTAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer	Fase Fase 2	Date Added 2016-02-26	Ubicación Alabama, United States Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Hawaii, United States Illinois, United States Indiana, United States Maine, United States Michigan, United States Nebraska, United States New Hampshire, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Wisconsin, United States	Prior IO Allowed Sí	CRC-directed No	Status Reclutamiento	Drogas Abemaciclib, afatinib, Atezolizumab and PHESGO, Atezolizumab and Talazoparib, Crizotinib, Entrectinib, Larotrectinib, Nivolumab and Ipilimumab, Olaparib, palbociclib, Pembrolizumab, Regorafenib, Sunitinib, Talazoparib, Temsirolimus, Trastuzumab and Pertuzumab, Tucatinib plus Trastuzumab Subcutaneous (SC), Vemurafenib and Cobimetinib, Cotellic, Herceptin, Perjeta, Zelboraf	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03599765	TitleTerapia sistémica con o sin terapia local consolidada en el tratamiento de pacientes con tumor sólido oligometastásico	Fase Fase 2	Date Added 2018-07-26	Ubicación Arizona, United States Arkansas, United States Hawaii, United States Michigan, United States New Jersey, United States Ohio, United States Texas, United States	Prior IO Allowed Sí	CRC-directed No	Status Activo, no recluta	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04599140	TitleSX-682 y nivolumab para el tratamiento del cáncer colorrectal metastásico o irresecable con mutación del RAS, el ensayo STOPTRAFFIC-1	Fase Fase 1	Date Added 2020-10-22	Ubicación Texas, United States	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas CXCR1/2 Inhibitor SX-682, Nivolumab	Etiquetas MSS/ MMRp
NCT ID NCT04653480	TitleSurufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC	Fase Fase 2	Date Added 2020-12-04	Ubicación China	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas Chemotherapy, Surufatinib, Toripalimab	Etiquetas MSS/ MMRp
NCT ID NCT06014502	TitleStudy to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors	Fase Fase 1	Date Added 2023-08-28	Ubicación Louisiana, United States Texas, United States	Prior IO Allowed No	CRC-directed No	Status Reclutamiento	Drogas IMGS-001	Etiquetas MSI-H/ MMRd
NCT ID NCT04659382	TitleStudy to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer	Fase Fase 2	Date Added 2020-12-09	Ubicación Francia	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas Atezolizumab, Bevacizumab, TheraSphere, XELOX	Etiquetas MSS/ MMRp

Showing 21 to 30 of 299 entries